Danaher Co. (NYSE:DHR) Shares Acquired by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 778.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,808 shares of the conglomerate’s stock after buying an additional 8,692 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Danaher were worth $2,252,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DHR. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher during the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher in the third quarter worth $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the third quarter valued at $50,000. Darwin Wealth Management LLC acquired a new stake in shares of Danaher during the third quarter worth $55,000. Finally, Modus Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth about $56,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Raymond James reduced their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Evercore ISI increased their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Stock Up 2.0 %

DHR opened at $239.83 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $173.22 billion, a PE ratio of 45.77, a P/E/G ratio of 4.32 and a beta of 0.83. The stock’s fifty day moving average is $235.52 and its 200-day moving average is $253.65. Danaher Co. has a one year low of $222.53 and a one year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.